Loading, please wait...
Date: Nov 11, 2022 02:00 PM - 02:45 PM
Location: UIW Feik School of Pharmacy, 703 E. Hildebrand, San Antonio, TX, 78212
CE Hours
1.00
CE Units
0.100
Registration closes on Dec 23, 2022 11:55 PM
Activity Type
- Application
Target Audience(s)
- Pharmacists
Accreditation(s)
|
The University of the Incarnate Word Feik School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
- The participant will only receive credit for programs after receiving a 70% on a post-test and an evaluation form is completed and submitted.
- The entire session must be attended to receive credit. No partial credit will be given.
- Certificates will not be mailed. Contact hours will be uploaded to NABP's CPE Monitor after successful completion of post-test and program evaluation.
- To receive credit, participant profiles must contain a valid NABP e-profile ID number and month/date of birth.
- All requirements to receive credit must be completed within six weeks of participation in the CPE program. Failure to complete requirements within the six-week window will result in no credit awarded to the participant.
Registration closes on Dec 23, 2022
at 11:55 PM
Registration closes on Dec 23, 2022
at 11:55 PM
Registration Closed
Registration Closed
Upon completion of this activity, pharmacists will be able to:
1. Identify the place in therapy of erythropoiesis-stimulating agents (ESA) for the treatment of anemia of chronic kidney disease (CKD) in patients undergoing hemodialysis (HD)
2. Recognize the black box warnings associated with erythropoiesis-stimulating agents (ESA)
3. Describe the effects of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) on erythropoietin, hepcidin, and iron
4. Summarize current literature comparing the use of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) to erythropoiesis-stimulating agents (ESA) for the treatment of anemia of chronic kidney disease (CKD) in patients undergoing hemodialysis (HD)
5. Given a patient case, select an appropriate treatment regimen for a patient with anemia of chronic kidney disease (CKD) undergoing hemodialysis (HD)
Speaker(s)/Author(s)
|
Sarah Edwards |
Activity Number
0445-0000-22-020-L01-P
Date:
11/11/22
Time:
02:00 PM - 02:45 PM
CE Hours
1.00
Location
https://teams.microsoft.com/l/meetup-join/19%3amee
Registration Closed